Press releases

Press releases

Inotrem expands Series B financing to €58 Million with a mix of Equity and Debt, adding new investors Fountain Healthcare Partners, Kreos and Bpifrance

Paris, February 11th, 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and chronic inflammatory syndromes, announced a €5M capital increase financed by Fountain Healthcare Partners, a leading Irish venture capital firm with offices in Dublin and New

February 11, 2020

Press releases

Inotrem was chosen to join the French Tech 120

January 20. 2020. Paris, France. Inotrem was chosen to join the French Tech 120. This program, launched by the President of the Republic and the Prime Minister in September 2019, is dedicated to support the development of fast growing startups. The French Tech Mission brings together some 50 French Tech

January 20, 2020

Press releases

Inotrem secures strategic licensing agreement for a companion diagnostics test in septic shock.

January 21. 2020. Paris, France. Inotrem has entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein (sTREM-1). This agreement consolidates existing ties between Roche Diagnostics and Inotrem who are jointly developing since 2017 an in vitro assay

January 20, 2020

Press releases

Inotrem Announces Enrollment of First Patient in its Phase IIb ASTONISH Trial for Nangibotide in the Treatment of Septic Shock

Paris (France). November 21. 2019. Inotrem S.A., a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, through its knowledge of the TREM-1 pathway biology, announced today it has initiated its Phase IIb ASTONISH trial to evaluate nangibotide in the treatment of septic shock and has enrolled the first patient

November 21, 2019

Press releases

Inotrem announces €39 Million Series B Financing to Develop First- In-Class Immunology Therapeutics

Paris, September 12th. 2019. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and chronic inflammatory syndromes,announced today a €39 million Series B financing led by Morningside Ventures, joined byInvus with participation from existing investors Andera Partners, Sofinnova Partners

September 12, 2019

Press releases

Inotrem Announces Fast Track Designation Granted by U.S. FDA to Nangibotide development program for the Treatment of Septic Shock

Paris, September 3rd. 2019. Inotrem S.A., a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nangibotide development program for the treatment of septic shock. Nangibotide, which Phase IIb has just been

September 4, 2019

Press releases

Inotrem announces FDA clearance of Investigational New Drug (IND) for the phase IIB ASTONISH trial in septic shock patients to demonstrate nangibotide efficacy

Paris (France). August 6. 2019. Inotrem S.A., a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, announced today the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for the ASTONISH trial (Phase IIb) where the safety, tolerance and efficacy of nangibotide (LR12),

August 6, 2019

Inotrem announces positive results from the Phase IIa study of its lead compound, nangibotide (LR12), in the treatment of septic shock.

The study demonstrated the safety and tolerability of its lead compound in patients suffering from septic shock Paris, October 1st. 2018. Inotrem S.A., a biotechnology focused on the modulation of the TREM pathway for the management of inflammatory syndromes, announced positive results for its Phase IIa study that demonstrated the

September 30, 2018

Martin Koch joins Inotrem as Chief Operating Officer

Paris, January 18th . 2018. Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes such as septic shock, has appointed Martin Koch as Chief Operating Officer (COO). Martin Koch comes to Inotrem with more than 25 years of experience in the healthcare industry. Prior to joining

January 18, 2018

Inotrem granted access to priority medicines scheme (PRIME) for its lead compound MOTREM™ in the treatment of septic shock.

Paris, November 15, 2017. Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes, today announced that the European Medicines Agency (EMA) has granted access to its PRIority MEdicines (PRIME) scheme for its lead product MOTREMTM in the field of septic shock.

November 15, 2017

Categories